Markets:

Overview

News

Currencies

International

Treasuries

Ligand Pharmaceuticals Incorporated - Common Stock (NQ:LGND)

197.72 +5.09 (+2.64%)

Streaming Delayed Price Updated: 3:37 PM EDT, Mar 31, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Ligand Pharmaceuticals Incorporated - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

Ligand Pharmaceuticals Sees RS Rating Rise To 92 ↗

November 11, 2021

A Relative Strength Rating upgrade for Ligand Pharmaceuticals shows improving technical performance.

Via Investor's Business Daily

Ligand To Spin-Off OmniAb Platform Into Its Own Independent Company ↗

November 10, 2021

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced plans to split into two separate publicly traded companies. One company will feature the OmniAb...

Via Benzinga

Ligand Pharmaceuticals Incorporated (LGND) Q3 2021 Earnings Call Transcript ↗

November 10, 2021

LGND earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

Recap: Ligand Pharmaceuticals Q3 Earnings ↗

November 09, 2021

Ligand Pharmaceuticals (NASDAQ:LGND) reported its Q3 earnings results on Tuesday, November 9, 2021 at 04:01 PM. Here's what investors need to know about the announcement....

Via Benzinga

Ligand Reports Third Quarter 2021 Financial Results

November 09, 2021

From Ligand Pharmaceuticals Incorporated

Via Business Wire

Ligand Pursuing Plans for OmniAb to Become a Standalone Public Company

November 09, 2021

From Ligand Pharmaceuticals Incorporated

Via Business Wire

The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data ↗

November 09, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For Acceleron Deal In Germany, Austria, Announces...

Via Benzinga

The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More ↗

November 08, 2021

Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out...

Via Benzinga

Ligand to Report Third Quarter Financial Results on November 9, 2021

October 26, 2021

From Ligand Pharmaceuticals Incorporated

Via Business Wire

Ligand Outlicenses BEPro Tech To Develop Oral COVID-19 Antivirals ↗

October 21, 2021

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) has signed a collaboration agreement with Double-Crane Pharmaceutical Co Ltd (CRDC). The agreement grants...

Via Benzinga

Ligand and CR Double-Crane Enter Collaboration Agreement to Develop an Oral COVID-19 Therapeutic Using Ligand’s BEPro Technology™

October 21, 2021

From Ligand Pharmaceuticals Incorporated

Via Business Wire

Ligand Pharmaceuticals Stock Shows Rising Price Performance ↗

September 22, 2021

A Relative Strength Rating upgrade for San Diego-based Ligand Pharmaceuticals stock shows improving technical performance.

Via Investor's Business Daily

Ligand Pharmaceuticals Stock Shows Market Leadership With Jump To 82 RS Rating ↗

September 20, 2021

Ligand Pharmaceuticals stock saw a positive improvement to its Relative Strength (RS) Rating on Monday, rising from 71 to 82.

Via Investor's Business Daily

Why Digital Turbine's Stock Is Trading Higher Today ↗

August 31, 2021

Digital Turbine Inc (NASDAQ: APPS) is trading higher Tuesday after it was announced the company is set to join the S&P MidCap 400. Digital Turbine will replace ...

Via Benzinga

Topics Stocks

Digital Turbine Added To S&P MidCap 400 Index ↗

August 31, 2021

Media and mobile communications company Digital Turbine Inc (NASDAQ:

Via Benzinga

Topics Stocks

The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical ↗

August 31, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26) Agenus Inc. (NASDAQ: AGEN)...

Via Benzinga

Ligand’s Partner Gloria Biosciences Receives Approval in China for Zimberelimab for the Treatment of Recurrent or Refractory Classical Hodgkin’s Lymphoma

August 30, 2021

From Ligand Pharmaceuticals Incorporated

Via Business Wire

Ligand Partner Travere Therapeutics Announces Positive Topline Interim Results from the Ongoing Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy

August 16, 2021

From Ligand Pharmaceuticals

Via Business Wire

What To Know About Rand Paul Failing To Disclose Gilead Stock Purchase For 16 Months ↗

August 12, 2021

Stock transactions by members of the U.S. Congress and their spouses have been a hot topic over the last several years. A transaction disclosed late Wednesday is drawing heavy...

Via Benzinga

Ligand Pharmaceuticals Incorporated (LGND) Q2 2021 Earnings Call Transcript ↗

July 30, 2021

LGND earnings call for the period ending June 30, 2021.

Via The Motley Fool

Topics Earnings

Ligand Reports Second Quarter 2021 Financial Results

July 29, 2021

From Ligand Pharmaceuticals Incorporated

Via Business Wire

The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs ↗

July 29, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 28) AbbVie Inc. (NYSE: ABBV)...

Via Benzinga

The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More ↗

July 25, 2021

Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was set in motion by the solid start...

Via Benzinga

Ligand Partner Jazz Pharmaceuticals Launches RYLAZE™ (asparaginase erwinia chrysanthemi (recombinant)-rywn), Formerly JZP458

July 21, 2021

From Ligand Pharmaceuticals Incorporated

Via Business Wire

Ligand’s Partner Merck Receives FDA Approval for VAXNEUVANCE™ for the Prevention of Invasive Pneumococcal Disease in Adults Caused by 15 Serotypes

July 19, 2021

From Ligand Pharmaceuticals Incorporated

Via Business Wire

The Week Ahead In Biotech: Earnings Kickstart With J&J And Biogen, Albireo Awaits FDA Decisions, More IPOs ↗

July 18, 2021

Biotech stocks were down for a second week in a row, as they retreated along with the broader market amid macro concerns. Consumer price inflation data released during the week...

Via Benzinga

Ligand to Report Second Quarter Financial Results on July 29, 2021

July 16, 2021

From Ligand Pharmaceuticals Incorporated

Via Business Wire

Ligand Pharmaceuticals Appoints Dr. Jennifer Cochran to its Board of Directors

July 14, 2021

From Ligand Pharmaceuticals Incorporated

Via Business Wire

Attention Biotech Investors: Mark Your Calendar For July PDUFA Dates ↗

July 01, 2021

June was a month of plenty and also turned out to be a fruitful one from the perspective of Food and Drug Administration approvals. Regulatory reviews mostly produced positive...

Via Benzinga

When Cap-Weighted Small-Cap Funds Own “Meme” Stocks ↗

May 13, 2021

I cannot say whether GameStop or the other meme stocks will get their businesses back on their feet. What I can say is that, if you are tracking various small-cap indexes, you just might own them, like...

Via Talk Markets

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.